⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Pathalys Pharma, Inc. and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Pathalys Pharma, Inc.
↗Raleigh, North Carolina, USA
Pathalys Pharma is a private, late-stage clinical biopharmaceutical company focused on developing advanced therapeutics to address unmet needs in the management of late-stage chronic kidney disease (CKD) and end-stage kidney disease (ESKD). The company was co-founded by Catalys Pacific and DaVita Venture Group to create a multi-asset pharmaceutical platform.
Its lead candidate, upacicalcet, is a novel calcimimetic designed to treat secondary hyperparathyroidism (SHPT) in hemodialysis patients. The company is currently focused on completing Phase 3 clinical trials and preparing for NDA submission to the FDA.
CLASSIFICATION
SIZE & FINANCIALS
Employees:51-200
Founded:2022
Ownership:private
Status:operating
FUNDING
Stage:Series B
Total Raised:$116M+
Investors:TCGX, JP Morgan Life Sciences Private Capital, Samsara BioCapital, Marshall Wace, KB Investment, JPS Growth Investment, Catalys Pacific, DaVita Venture Group, Abingworth
PIPELINE
Stage:Phase 3
Lead Drug Stage:Phase 3
Modalities:Small molecule
Active Trials:2
Trial Phases:Phase 3: 2
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:Launch Therapeutics (Strategic collaboration for Phase 3 program acceleration)
COMPETITION
Position:Emerging
LEADERSHIP
Key Executives:
Neal Fowler - CEO
Bastian Dehmel - Chief Medical Officer
BT Slingsby - Co-Founder and Executive Chairman
Scientific Founders:BT Slingsby, Catalys Pacific, DaVita Venture Group
Board Members:BT Slingsby, Neal Fowler, Bali Muralidhar, Joseph Siletto, Chen Yu
LINKS
Website:pathalys.com
LinkedIn:LinkedIn Profile
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Pathalys Pharma, Inc.. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.